{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:48:59Z","timestamp":1791838139189,"version":"4.3.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.isci.2026.115849","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T16:16:31Z","timestamp":1776788191000},"page":"115849","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bi-functional anti-LAG-3-IL-2c enhances immune checkpoint inhibitor and CAR T-cell therapy for cancer"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1299-093X","authenticated-orcid":false,"given":"Fang","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianing","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih Chieh","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Botong","family":"Hua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella Yumin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Kwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenli","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingxing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binfeng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyang","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2026.115849_bib1","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2024.2378543","article-title":"Approved CAR-T therapies have reproducible efficacy and safety in clinical practice","volume":"20","author":"Goyco Vera","year":"2024","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.isci.2026.115849_bib2","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s40291-025-00771-z","article-title":"Obecabtagene Autoleucel: First Approval","volume":"29","author":"Lee","year":"2025","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.isci.2026.115849_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1113882","article-title":"The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies","volume":"14","author":"Daei Sorkhabi","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.115849_bib4","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41388-020-01501-x","article-title":"Counteracting CAR T cell dysfunction","volume":"40","author":"Poorebrahim","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.isci.2026.115849_bib5","doi-asserted-by":"crossref","first-page":"702","DOI":"10.3389\/fimmu.2020.00702","article-title":"Prolonged Persistence of Chimeric Antigen Receptor (CAR) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward","volume":"11","author":"Jafarzadeh","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.115849_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.684642","article-title":"Engineered Cytokine Signaling to Improve CAR T Cell Effector Function","volume":"12","author":"Bell","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.115849_bib7","doi-asserted-by":"crossref","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","article-title":"Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma","volume":"118","author":"Louis","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.115849_bib8","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","article-title":"Clinical lessons learned from the first leg of the CAR T cell journey","volume":"25","author":"Majzner","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.115849_bib9","doi-asserted-by":"crossref","first-page":"645","DOI":"10.3390\/ijms18030645","article-title":"TIM-3 as a Target for Cancer Immunotherapy and Mechanisms of Action","volume":"18","author":"Du","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2026.115849_bib10","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.trecan.2024.10.009","article-title":"Advances in LAG3 cancer immunotherapeutics","volume":"11","author":"Adam","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.isci.2026.115849_bib11","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1200\/JCO.22.02072","article-title":"Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1\/Programmed Death Ligand 1 Therapy: Results From the Phase I\/IIa RELATIVITY-020 Trial","volume":"41","author":"Ascierto","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.115849_bib12","doi-asserted-by":"crossref","first-page":"16168","DOI":"10.1073\/pnas.242600099","article-title":"Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells","volume":"99","author":"Yee","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2026.115849_bib13","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1158\/1078-0432.CCR-15-1879","article-title":"Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen","volume":"22","author":"Andersen","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.115849_bib14","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nbt.4181","article-title":"Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery","volume":"36","author":"Tang","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.isci.2026.115849_bib15","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1158\/1078-0432.CCR-14-2085","article-title":"Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma","volume":"21","author":"Zhang","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2026.115849_bib16","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.1999.17.7.2105","article-title":"High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993","volume":"17","author":"Atkins","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.115849_bib17","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abg6986","article-title":"A human orthogonal IL-2 and IL-2R\u03b2 system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia","volume":"13","author":"Zhang","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.isci.2026.115849_bib18","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.115849_bib19","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.omto.2021.12.019","article-title":"Anti-CAIX BB\u03b6 CAR4\/8 T cells exhibit superior efficacy in a ccRCC mouse model","volume":"24","author":"Wang","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.isci.2026.115849_bib20","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1189\/jlb.0604341","article-title":"BALB\/c mice have more CD4+CD25+ T regulatory cells and show greater susceptibility to suppression of their CD4+CD25- responder T cells than C57BL\/6 mice","volume":"78","author":"Chen","year":"2005","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.isci.2026.115849_bib21","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.1016\/j.cell.2024.06.036","article-title":"Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity","volume":"187","author":"Cillo","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.115849_bib22","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.115849_bib23","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1158\/2326-6066.CIR-21-0831","article-title":"Discovery of a Conditionally Activated IL-2 that Promotes Antitumor Immunity and Induces Tumor Regression","volume":"10","author":"Nirschl","year":"2022","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.isci.2026.115849_bib24","first-page":"11","article-title":"Managing toxicities of high-dose interleukin-2","volume":"16","author":"Schwartz","year":"2002","journal-title":"Oncology"},{"key":"10.1016\/j.isci.2026.115849_bib25","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s002620050527","article-title":"Mechanisms of leukocyte-mediated tissue injury induced by interleukin-2","volume":"47","author":"Lentsch","year":"1999","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.isci.2026.115849_bib26","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0162-3109(97)00041-6","article-title":"Vascular leak syndrome: a side effect of immunotherapy","volume":"37","author":"Baluna","year":"1997","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.isci.2026.115849_bib27","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1277306","article-title":"Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines","volume":"6","author":"Klein","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.isci.2026.115849_bib28","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1913791","article-title":"Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy","volume":"13","author":"Waldhauer","year":"2021","journal-title":"mAbs"},{"key":"10.1016\/j.isci.2026.115849_bib29","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/s41586-022-05192-0","article-title":"PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells","volume":"610","author":"Codarri Deak","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.isci.2026.115849_bib30","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1126\/science.aar3246","article-title":"Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes","volume":"359","author":"Sockolosky","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.isci.2026.115849_bib31","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abg7565","article-title":"An orthogonal IL-2 and IL-2R\u03b2 system drives persistence and activation of CAR T cells and clearance of bulky lymphoma","volume":"13","author":"Aspuria","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.isci.2026.115849_bib32","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput. Methods Programs Biomed."},{"key":"10.1016\/j.isci.2026.115849_bib33","article-title":"AWT020: a novel fusion protein harnessing PD-1 blockade and selective IL-2 Cis-activation for enhanced anti-tumor immunity and diminished toxicity","volume":"16","author":"Ye","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.115849_bib34","article-title":"Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications","author":"Ye","year":"2024","journal-title":"U.S. Patent No. 11,897,930"},{"key":"10.1016\/j.isci.2026.115849_bib35","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nbt0798-677","article-title":"An efficient route to human bispecific IgG","volume":"16","author":"Merchant","year":"1998","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.isci.2026.115849_bib36","article-title":"Anti-Lag-3\/Il-2 Fusion Proteins, Encoding Polynucleotides, Pharmaceutical Compositions, and Therapeutic Applications","author":"Huang","year":"2024","journal-title":"International Patent Publication No. WO 2024\/073435"},{"key":"10.1016\/j.isci.2026.115849_bib37","article-title":"Immunosuppressant","author":"Okazaki","year":"2022","journal-title":"U.S. Patent Application Publication No. US 2022\/0227887"},{"key":"10.1016\/j.isci.2026.115849_bib38","doi-asserted-by":"crossref","first-page":"6017","DOI":"10.1074\/jbc.RA119.007455","article-title":"Atypical motifs in the cytoplasmic region of the inhibitory immune co-receptor LAG-3 inhibit T cell activation","volume":"294","author":"Maeda","year":"2019","journal-title":"J. Biol. Chem."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226012241?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226012241?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:39:12Z","timestamp":1791837552000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004226012241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2589004226012241"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2026.115849","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bi-functional anti-LAG-3-IL-2c enhances immune checkpoint inhibitor and CAR T-cell therapy for cancer","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2026.115849","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"115849"}}